Home › Companies › MRKR

Marker Therapeutics, Inc.

MRKR Lead: Phase 1 6 Biotech Distilled articles ↓

Oncology Cell

Most recent annual filing: 2026-03-15

Pipeline (4 active programs)

MT-601

Cell Target: NY-ESO-1, PRAME, MAGE-A4, Survivin, WT1, SSX2

MT-401-OTS

Cell Target: WT1, NY-ESO-1, PRAME, Survivin

Technology platforms

MAR-T · Baylor College of Medicine

Multi Antigen Recognizing T cell platform that selectively expands natural tumor-specific T cells from a patient's or donor's blood to recognize a broad range of tumor-associated antigens without genetic modification; applicable to hematological malignancies and solid tumors

Targets: NY-ESO-1, PRAME, MAGE-A4, Survivin, WT1, SSX2

Biotech Distilled coverage (6)

2026-05-16 UPDATE: Marker Therapeutics (MRKR) - Q1 Numbers, Stretched Runway, Stretched Vendors 🔒 Paid
2026-05-04 UPDATE: Marker Therapeutics (MRKR) - The Dilution Cannon Gets Loaded
2026-04-01 CORRECTION: Marker Therapeutics (MRKR) - MRKR’s Dilution Trap is Actually Bigger Than I Thought
2026-03-22 UPDATE: Marker Therapeutics (MRKR) - 10-K & Definitive Proxy Drop 🔒 Paid
2026-03-15 UPDATE: Marker Therapeutics (MRKR) - The Dilution Gap Becomes a Reality 🔒 Paid
2026-03-10 Marker Therapeutics (MRKR) - Scientific Deep Dive for and MT-601 and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.